Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601647 | 0.84 | MAPT (0.53) | TDP1PSMB8KDM4EALDH1A1MAPT | |
| SCHEMBL31143803 | 0.84 | MAPT (0.53) | TDP1PSMB8KDM4EALDH1A1MAPT | |
| SCHEMBL5673819 | 0.78 | TDP1 (0.58) | TDP1KDM4EPKMALDH1A1MAPT | |
| SCHEMBL29451077 | 0.75 | TDP1 (1.00) | TDP1KDM4EPKMALDH1A1MAPT | |
| SCHEMBL116696 | 0.75 | TDP1 (1.00) | TDP1KDM4EPKMALDH1A1MAPT | |
| SCHEMBL12630108 | 0.74 | ALDH1A1 (0.45) | PSMB8KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL11693530 | 0.74 | ALDH1A1 (0.42) | TDP1PSMB8KDM4EALDH1A1MAPT | |
| SCHEMBL22931800 | 0.74 | ALDH1A1 (0.42) | TDP1PSMB8KDM4EALDH1A1MAPT | |
| SCHEMBL29424973 | 0.74 | MAPT (0.58) | PSMB8KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL1128621 | 0.74 | MAPT (0.58) | PSMB8KDM4EALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017019817-A1 | METHODS AND COMPOSITIONS FOR TARGETED THERAPEUTICS | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019830-A1 | METHODS AND COMPOSITIONS FOR TARGETED THERAPEUTICS | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019822-A1 | PELLET COMPOSITION CONTAINING REPAIR CELLS | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| EP-1942905-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | LDLR, APOB, FFAR1 | TDP1 3017/4885PSMB8 2984/4885KDM4E 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.